These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 32358546)

  • 21. A Phase IIb, Multicenter, Open-Label, Safety, and Efficacy Study of High-Dose, Propylene Glycol-Free Melphalan Hydrochloride for Injection (EVOMELA) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation.
    Hari P; Aljitawi OS; Arce-Lara C; Nath R; Callander N; Bhat G; Allen LF; Stockerl-Goldstein K
    Biol Blood Marrow Transplant; 2015 Dec; 21(12):2100-2105. PubMed ID: 26327631
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluating the adverse effects of melphalan formulations.
    Xiang E; Ni J; Glotzbecker B; Laubach J; Soiffer R; McDonnell AM
    J Oncol Pharm Pract; 2019 Oct; 25(7):1631-1637. PubMed ID: 30336728
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of 1-day vs 2-day dosing of high-dose melphalan followed by autologous hematopoietic cell transplantation in patients with multiple myeloma.
    Parmar SR; Bookout R; Shapiro JF; Tombleson R; Perkins J; Kim J; Yue B; Tomblyn M; Alsina M; Nishihori T
    Bone Marrow Transplant; 2014 Jun; 49(6):761-6. PubMed ID: 24662419
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and efficacy of propylene glycol-free melphalan as conditioning in patients with AL amyloidosis undergoing stem cell transplantation.
    Sidiqi MH; Aljama MA; Muchtar E; Buadi FK; Warsame R; Lacy MQ; Dispenzieri A; Dingli D; Leung N; Gonsalves WI; Kapoor P; Kourelis TV; Hogan WJ; Wolf RC; Kumar SK; Gertz MA
    Bone Marrow Transplant; 2019 Jul; 54(7):1077-1081. PubMed ID: 30390060
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Phase I/II, Open-Label, Prospective, Multicenter Study to Evaluate the Efficacy and Safety of Lower Doses of Bortezomib Plus Busulfan and Melphalan as a Conditioning Regimen in Patients with Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation: The KMM103 Study.
    Park SS; Kim K; Kim SJ; Lee JH; Yoon SS; Mun YC; Lee JJ; Eom HS; Kim JS; Min CK;
    Biol Blood Marrow Transplant; 2019 Jul; 25(7):1312-1319. PubMed ID: 30910603
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluating the incidence of engraftment syndrome with different melphalan formulations in adult multiple myeloma and immunoglobulin light chain amyloidosis patients undergoing autologous hematopoietic cell transplantation.
    Kowalski KE; Wheeler SE; Adams CB; Voils SA; Richards AI
    J Oncol Pharm Pract; 2022 Mar; 28(2):274-281. PubMed ID: 33435822
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase II, single-arm, prospective study of bendamustine plus melphalan conditioning for second autologous stem cell transplantation in de novo multiple myeloma patients through a tandem transplant strategy.
    Martino M; Tripepi G; Messina G; Vincelli ID; Console G; Recchia AG; Gentile M; Molica S; Morabito F
    Bone Marrow Transplant; 2016 Sep; 51(9):1197-203. PubMed ID: 27088375
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oral mucositis and outcomes of autologous hematopoietic stem-cell transplantation following high-dose melphalan conditioning for multiple myeloma.
    Vera-Llonch M; Oster G; Ford CM; Lu J; Sonis S
    J Support Oncol; 2007 May; 5(5):231-5. PubMed ID: 17564153
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Impact of Renal Impairment in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation With Melphalan Conditioning.
    Ursu SG; Maples S; Williams KJ; Patrus G; Samhouri Y; Fazal S; Mewawalla P; Sadashiv S
    J Hematol; 2023 Oct; 12(5):201-207. PubMed ID: 37936977
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Toxicity assessment of concurrent gabapentin/pregabalin administration with high-dose melphalan in autologous hematopoietic cell transplant recipients.
    Angus J; Cumpston A; Veltri L; Ross KG; Wen S; Dillaman M
    Support Care Cancer; 2021 Dec; 29(12):7925-7930. PubMed ID: 34191128
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Icing oral mucositis: Oral cryotherapy in multiple myeloma patients undergoing autologous hematopoietic stem cell transplant.
    Chen J; Seabrook J; Fulford A; Rajakumar I
    J Oncol Pharm Pract; 2017 Mar; 23(2):116-120. PubMed ID: 26684614
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study.
    Lahuerta JJ; Mateos MV; Martínez-López J; Grande C; de la Rubia J; Rosiñol L; Sureda A; García-Laraña J; Díaz-Mediavilla J; Hernández-García MT; Carrera D; Besalduch J; de Arriba F; Oriol A; Escoda L; García-Frade J; Rivas-González C; Alegre A; Bladé J; San Miguel JF;
    Haematologica; 2010 Nov; 95(11):1913-20. PubMed ID: 20663944
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.
    Rodriguez TE; Hari P; Stiff PJ; Smith SE; Sterrenberg D; Vesole DH
    Biol Blood Marrow Transplant; 2016 Aug; 22(8):1391-1396. PubMed ID: 27164062
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics of High-Dose Propylene Glycol-Free Melphalan in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation.
    Dhakal B; D'Souza A; Lakshman A; Hamadani M; Chhabra S; Thompson R; Shah N; Pasquini M; Hari P
    Biol Blood Marrow Transplant; 2018 Aug; 24(8):1610-1614. PubMed ID: 29751116
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
    Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
    Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II Study of Propylene Glycol-Free Melphalan Combined with Carmustine, Etoposide, and Cytarabine for Myeloablative Conditioning in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation.
    Cashen AF; Fletcher T; Ceriotti C; Gao F; Ghobadi A; Vij R; Stockerl-Goldstein K; DiPersio J; Abboud C
    Biol Blood Marrow Transplant; 2016 Dec; 22(12):2155-2158. PubMed ID: 27575541
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Autologous stem cell transplantation for multiple myeloma patients aged ≥ 75 treated with novel agents.
    Vaxman I; Visram A; Kumar S; Dispenzieri A; Buadi F; Dingli D; Lacy M; Muchtar E; Kapoor P; Hogan W; Hayman S; Leung N; Gonsalves W; Kourelis T; Warsame R; Berger T; Gertz MA
    Bone Marrow Transplant; 2021 May; 56(5):1144-1150. PubMed ID: 33273658
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support.
    Vogl DT; Liu SV; Chong EA; Luger SM; Porter DL; Schuster SJ; Tsai DE; Perl A; Loren AW; Goldstein SC; Nasta SD; Andreadis C; Mangan PA; Hummel K; Siegel DL; Glatstein E; Stadtmauer EA
    Am J Hematol; 2007 Dec; 82(12):1071-5. PubMed ID: 17696204
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized phase II trial of fludarabine/melphalan 100 versus fludarabine/melphalan 140 followed by allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma.
    Bashir Q; Khan H; Thall PF; Liu P; Shah N; Kebriaei P; Parmar S; Oran B; Ciurea S; Nieto Y; Jones R; Hosing CM; Popat UR; Dinh YT; Rondon G; Orlowski RZ; Shah JJ; De Lima M; Shpall E; Champlin R; Giralt S; Qazilbash MH
    Biol Blood Marrow Transplant; 2013 Oct; 19(10):1453-8. PubMed ID: 23872222
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Propylene Glycol-Free Melphalan versus PG-Melphalan as Conditioning for Autologous Hematopoietic Cell Transplantation for Myeloma.
    Monahan K; Kleman A; Thapa B; Szabo A; D'Souza A; Dhakal B; Jerkins JH; Pasquini MC; Hamadani M; Hari PN; Chhabra S
    Biol Blood Marrow Transplant; 2020 Dec; 26(12):2229-2236. PubMed ID: 32920204
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.